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Abstract
Background: The way in which pragmatic trials are designed suggests that there are differences between the
experiences of participants randomised to usual care and intervention arms. These potential differences relate not
only to which treatment participants receive but also how they access and engage with their allocated treatment.
Such differences could affect trial results. The aim of this study was to assess whether such differences exist and, if
they do, to consider their implications for the design of future trials.
Methods: Interview transcripts were sampled from data sets gathered during three qualitative studies, all of which
had been nested within large, primary care depression trials. Each study had explored trial participants’ views and
experiences of treatments received following randomisation. Transcripts from 37 participants were purposefully
sampled, 20 of which were from interviews held with individuals allocated to receive usual GP care. Data were
analysed thematically.
Results: There was evidence of differences between trial arms across all three data sets. Intervention participants were
willing and able to engage with the treatment to which they had been allocated. Randomisation had led to them
embarking upon a clear treatment pathway and receiving care in a context where they felt comfortable discussing
their mental health and had sufficient time to do so. Intervention participants also had continuity with and confidence
in the practitioners they saw. A few usual-care participants talked about having continuity with and confidence in their
GPs. However, most of the usual-care participants reported a reluctance to consult GPs about mental health, difficulties
in securing treatment appointments, and little or no changes in care following randomisation. Additionally, most
reported a lack of continuity of care and a lack confidence in the treatment available to them.
Conclusions: There are important differences between usual-care and intervention arms that go beyond treatment
received, and they relate to how participants experience accessing and engaging with their allocated care. As these
differences could affect trial results, researchers may want to measure or reduce them in order to fully appreciate or
control for the range of factors that might affect treatment outcomes.
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Background
Randomised controlled trials are viewed as the most ap-
propriate research design for evaluating the effectiveness
of health-care interventions [1]. Clinical trials are usually
pragmatic in nature, i.e. they measure the benefit treat-
ments produce in routine clinical practice [2], and often
aim to assess the effectiveness of a new or modified
treatment against ‘treatment as usual’.
Pragmatic trials often evaluate complex interventions
(i.e., interventions that include several interacting com-
ponents) [3]. Guidance on the development and evalu-
ation of complex interventions [4] emphasises various
phases which should be undertaken prior to full evalu-
ation within a trial. These phases include reviewing
existing evidence, developing a theoretical understanding
and conducting feasibility and pilot studies. Following
such guidance should result in the intervention being
clearly defined prior to the trial starting.
There is less guidance on how to establish the usual-care
arm of a trial, and this arm is often poorly defined [5, 6].
Furthermore, whilst usual care is often unrestricted ‘treat-
ment as usual’, researchers may choose to prescribe exactly
which treatment(s) individuals in the usual-care arm will
receive [7]. Dawson et al. [8] argued that how researchers
define usual care should be informed by factors such as the
research question, current evidence and what variability ex-
ists within current practice.
When interpreting trial results, researchers tend to
focus primarily on what treatment participants in differ-
ent trial arms received, in terms of type and amount
(see, e.g., [9–12]). This focus is very narrow. Treatment
is a process, and patients’ experiences of accessing and
receiving care could also influence their treatment out-
comes and thus the trial’s results. This is because a pa-
tient’s treatment experiences can influence the extent to
which the patient engages with treatment [13]. It is im-
portant that trialists acknowledge this because the way
in which trials are designed suggests there are variations
between the experiences of patients randomised to inter-
vention and usual-care arms regarding factors such as
support to access treatment. If this is the case, to appro-
priately evaluate an intervention and to consider the
range of factors that might explain outcome differences
between trial arms, researchers need to appreciate how
patients set about accessing and engaging with the care
to which they have been allocated.
Research funders continue to view mental health re-
search as a priority area [14]. It is predicted that depres-
sion and anxiety will be the leading causes of disability
in high-income countries by 2030 [15]. In the United
Kingdom, most of this disease burden is managed in pri-
mary care. Current interventions include pharmacother-
apy and psychological interventions such as cognitive
behavioural therapy (CBT). In addition, physical activity
may be offered to patients with mild to moderate de-
pression [16], and specific treatments may be available
to particular groups of patients; for example, health visi-
tors can provide listening visits to women with post-
natal depression. Further research is needed because,
despite the availability of different treatments for depres-
sion, some patients do not respond to antidepressants
[17] or recover despite receiving both pharmacotherapy
and psychological intervention [18].
We conducted a secondary analysis and synthesis of
data collected during three qualitative studies, all of
which were nested within large, multi-centred, pragmatic
primary care depression trials. Our aim was to bring to-
gether participants’ accounts of their experiences follow-
ing randomisation in order to assess whether there are
differences between the experiences of individuals in dif-
ferent trial arms that researchers may want to consider
when designing future trials and evaluating complex
interventions.
Methods
Data set
The lead author was confident that the three data sets
selected for this study would accommodate its aim.
KMT had led the original studies and therefore was fa-
miliar with each data set. In addition, she was aware that
each study had entailed conducting in-depth interviews
with trial participants to explore their experiences in the
trial and the treatments received.
Data were collected between 2006 and 2011. Partici-
pants were interviewed after having completed their pri-
mary or final outcome measures within the trial (i.e.,
between 4 and 12 month post-randomisation). In one of
the studies, individuals were interviewed on two occa-
sions (Table 1). The first interview had focused on the
participants’ initial trial and treatment experiences. The
second interview was held 8 months later and
assessed participants’ experiences during the later
stages of the trial. In total, the data set consisted of
121 interview transcripts.
Trials
The trials hosting the qualitative studies recruited indi-
viduals through general practitioner (GP) surgeries lo-
cated in the United Kingdom. In each trial
randomisation had occurred at the level of the individ-
ual, and participants had been allocated to one of two
treatment arms. Treatments being evaluated included
antidepressants, CBT, facilitated physical activity and lis-
tening visits. They were delivered by various indivi-
duals—GPs, CBT therapists, physical activity facilitators
(PAFs) and research health visitors (RHVs)—and were
aimed at different patient groups with depression (i.e.,
patients with a new episode of depression, patients with
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treatment-resistant depression and women with post-
natal depression).
In two of the trials (trials 1 and 2), individuals were al-
located either to an intervention plus usual care or to
usual care only. Usual care was defined as the care the
individual would normally receive from his/her GP. In
the third trial, women diagnosed with post-natal depres-
sion were randomised to initially receive either antide-
pressants from their GP or listening visits from an RHV.
Women randomised to antidepressants were asked to
contact their GP.
Secondary analysis and synthesis of the data
Data were analysed by two of the authors, one of whom
(KMT) was familiar with the material and could provide
details about the trials and the context in which data
had been collected, and another of whom (JP) was
‘naive’ to the material and able to bring a new perspec-
tive to the data sets. Both authors are experienced health
service researchers with particular expertise in analysing
interview data.
Initially, KMT and JP independently read and re-read a
sample of six transcripts to gain an overall sense of the
data and to consider how the data should be analysed.
These transcripts were purposefully sampled from across
the three studies to ensure maximum variation in terms
of trial arm and participant gender and age. It was
agreed that a thematic approach should be taken
because this would enable comparisons to be made
across the data sets. Having agreed on this approach,
KMT and JP re-read the sampled transcripts and noted
possible codes. They then met to discuss their codes and
to agree on a coding frame. Once agreement was
reached, KMT and JP independently coded the sampled
transcripts, then met again to compare their coding and
to discuss any discrepancies. This discussion led to new
codes being added and existing codes being deleted or
defined more clearly. Having finalised the coding frame,
they sampled further transcripts using the purposeful
approach detailed above. These transcripts, along with
the initial six, were imported into NVivo [19] and elec-
tronically coded by KMT. This allowed the researchers
to then electronically retrieve data pertaining to specific
codes and analyse them in detail. To enable comparisons
to be made within and across the data sets, using an ap-
proach based on Framework analysis [20], KMT sum-
marised the data retrieved in a set of tables. The tables
were formatted so that the rows represented each
interviewee and columns represented the codes devel-
oped. Having summarised the data, KMT and JP scru-
tinised the content of the table columns to identify
central themes and deviant cases. Transcripts were
sampled until it was felt that analysing further tran-
scripts would not provide any additional insights; that
is, transcripts were sampled until data saturation had
been reached.
Table 1 Details of the trials and the nested qualitative studies
Trial Trial aim Trial design Intervention treatment Patients intervieweda
1 Assess the clinical effectiveness
and cost-effectiveness of a facilitated
physical activity intervention plus
usual care, versus usual care alone,
for patients with a new episode of
depression
Patients randomised to
receive a physical activity
intervention plus usual
care or usual care alone
The physical activity intervention
was delivered by physical activity
facilitators. It consisted of a maximum
of 13 sessions; one 1-h face-to-face
session, two 45-minute face-to-face
sessions and ten 10- to 20-minute
telephone sessions.
Thirty-three trial participants
interviewed at 4 months post-
randomisation, having completed
their primary outcome measures
for the trial. Nineteen had been
randomised to facilitated activity
plus usual care, the rest to usual
care only. Twenty-one of the 33
were interviewed again
9 months later.
2 Examine the clinical effectiveness
and cost-effectiveness of CBT plus
usual care, versus usual care alone,
for patients with treatment-resistant
depression
Participants randomised
to face-to-face CBT plus
usual care or usual care only
Face-to-Face CBT was delivered
by CBT therapists. Patients were
allowed up to eighteen 1-h
sessions.
Forty trial participants were
interviewed 6 months post-
randomisation, having completed
their primary outcome measures
for the trial. Twenty-six had been
randomised to CBT plus usual
care and 14 to usual care only.
3 Evaluate the clinical effectiveness of
antidepressants compared with general
supportive care, and to evaluate the
clinical effectiveness and cost-
effectiveness of antidepressants
compared with listening visits as an
initial treatment for post-natal
depression
Participants randomised to
antidepressants or listening
visits but could ‘cross’
treatment arms after 4 weeks
post-randomisation
Listening visits were delivered by
research health visitors. The visits
lasted 1-h each. Women were
allowed up to eight visits in total.
Twenty-seven trial participants
were interviewed at 44 weeks
post-randomisation, having
received treatment in the trial.
Seventeen had been randomised
to initially receive listening visits,
and ten had been allocated to
initially receive antidepressants.
CBT Cognitive behavioural therapy
aTrial 1 interviews were held between March and November 2009 and between November 2009 and July 2010. Trial 2 interviews were held between April 2010
and February 2011. Trial 3 interviews were held between November 2006 and June 2007
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Results
Forty-four transcripts were analysed in total. Because 7
of these transcripts were from second interviews with
participants whose first interviews had been analysed,
we had data from 37 participants (Table 2). Twenty of
these participants had been randomised to receive care
from their GP, either having been allocated to usual care
(trials 1 and 2) or having been randomised to initially re-
ceive an antidepressant (trial 3). These participants were
viewed as being in the usual-care arm of their trial.
Analysis of the data indicated differences between trial
arms regarding participants’ willingness to engage with
their allocated treatment and practitioner, the ease with
which they could access care, their treatment experiences
and their view of their practitioner. Quotes are provided
below to illustrate some of the points made. These quotes
are tagged according to the participant’s trial, treatment
allocation and assigned identification number. When re-
ferring to individuals who delivered care within an inter-
vention arm, the term therapist is used.
Reaction to treatment allocation and willingness to
consult
Two ‘intervention participants’ described how they were
nervous about starting a new treatment, and some men-
tioned being concerned that they might not be able to
schedule the treatment sessions around their other com-
mitments. Most intervention participants, however, indi-
cated that they were pleased with their allocation and
keen to start treatment, describing it as ‘a really good re-
sult’ (trial 1, intervention, participant 13) and ‘what my
aim was’ (trial 2, intervention, participant 3). In contrast,
many of the usual-care participants said they had been
disappointed by their allocation, and they felt that they
had missed an opportunity to receive a treatment which
would benefit them and would now receive inferior care
to individuals in the intervention arm:
I was gutted [having been allocated to usual care].… I
remember leaving and just feeling utter despair. I
thought that, genuinely at the time I thought that was
my last chance. (Trial 2, usual care, participant 29)
It did occur to me that it must be blatantly obvious
that the people that are having both [treatments] are
going to be better off, because I mean nothing’s
changed for me at all, so I mean what’s the point of
comparing the two. (Trial 2, usual care, participant 21)
With the exception of trial 3, where women had been
asked to contact their GP to start medication, in the ac-
counts there was very little evidence that individuals
randomised to receive usual care had made a GP ap-
pointment in response to their allocation. This suggested
that in trials 1 and 2, randomisation to usual care had
not led to participants seeking additional care or viewing
the trial as an opportunity for their current treatment to
be reviewed. This may have been because they felt there
was no expectation that their behaviour would change,
because a few of the usual-care participants talked about
being in the control or placebo group. Another reason
could be because participants were reluctant to seek
help from their GP.
Intervention and usual-care participants in all three
trials talked about how they were hesitant to consult
their GP about their mental health. Reasons given in-
cluded previous negative GP consultations, worrying
that they would be viewed as ‘crazy’ (Trial 2, usual
care, participant 29), and being concerned that they
would need to initiate a conversation about their
mental health. Some patients linked this concern to
the fact that they had experienced little continuity in
terms of which GP they had seen. This led to patients
feeling they would need to explain again how they
felt, assuming that if they did consult, there was no
guarantee they would see the same GP again, and
feeling that they had no relationship with a specific
practitioner, which in turn led them to worry that
they would waste the practitioner’s time:
Interviewer: And how did you feel about going to
your GP?
Participant: I kind of thought I didn’t want to waste
their time, because I didn’t have a relationship with
my doctor; you’re lucky if you see the same doctor
more than twice, so going in and talking to them
Table 2 Participants’ details (n = 37)
Trial
1 15
2 12
3 10
Trial arm
Intervention 17
Usual care 20
Sex
Male 12
Female 25
Age, years
20–29 6
30–39 13
40–49 8
50–59 5
60 and older 5
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about it, I felt a bit of a fraud. (Trial 3, usual care,
participant 1)
Within the accounts there was also the suggestion that
individuals were hesitant to seek help because there was
nothing physically wrong with them:
It’s not like having a physical illness.… You’re never
disbelieved if you’ve got a broken leg; if your brain’s not
working, it takes an awful lot of, for somebody like me
who doesn’t, I don’t like opening up, or didn’t, didn’t like
opening up to people because I thought it would be poo-
pooed. (Trial 2, usual care, participant 24)
Another reason participants gave for not wanting to
consult their GP was because they did not want to be
prescribed an antidepressant due to concerns about
medication dependency, side effects and being stigma-
tised. Last, it was apparent that some participants
were reluctant to consult their GPs because they
viewed GPs as generalists who did not know about
mental health issues:
People keep telling me I should actually go to see the
doctor again, but I haven’t got a lot of faith in GPs
because I know they’re GPs, they’re general practitioners,
they don’t know about these things.… [I]t doesn’t do a
lot of good seeing your GP really. (Trial 2, usual care,
participant 21)
The difference between participants in different trial
arms being willing to engage with their allocated
treatment suggested there would be discrepancies
between the arms in terms of whether participants
accessed care. This situation seemed further exacer-
bated by the fact that intervention and usual-care
participants differed in how easily they had found it
to secure an appointment.
Securing a treatment appointment
Individuals randomised to intervention arms were con-
tacted shortly after randomisation by the therapist who
would be responsible for their care, to arrange their ini-
tial appointment. When describing their experiences of
making further appointments, they described how this
had been straightforward; they had been able to contact
their therapist directly, either by mobile telephone and/
or email address, and in the case of some participants,
their therapist had agreed to appointment times that
worked around the patient’s other commitments.
Already noted is that some usual-care participants
were reluctant to contact their GP. Within the usual-
care transcripts, practical barriers were also mentioned.
Participants described how their GP practice allowed
patients to book only so many days in advance and de-
scribed how it was often difficult to see a specific GP be-
cause that GP only worked part-time or because the GP
was popular and therefore fully booked. For individuals
who worked, practice opening times and geographical
distance were also mentioned:
I find it very difficult to get to my doctor’s because they
don’t open during the times that I can get to them.
And because I work 25 miles away, it’s really difficult
for me to get in to discuss anything. (Trial 1, usual
care, participant 11)
Experiences of receiving care
Accounts from most of the intervention participants
suggested they had been on a clear care pathway. They
talked about booking appointments ahead, regularly
seeing their therapist and knowing what care they were
able to receive (e.g., number of sessions, when and
where). The trials had been designed so that individuals
randomised to an intervention arm would have continuity
of care in terms of which therapist they saw. As interven-
tion participants talked about receiving care from the
same therapist, it was evident that this had occurred. They
described this continuity of care as allowing them to build
a relationship with their therapists and learn to trust them,
revisit ideas and agree on goals to work towards. Continu-
ity of care was also described as creating a sense of
partnership and increasing the individual’s commitment
to their treatment:
Interviewer: So it wasn’t a question of just being told,
it was something you had to?
Participant: It was something I worked through with
[PAF’s name]. I didn’t get on with it [exercising] I’d be
letting her – letting [PAF’s name] down. (Trial 1,
intervention, participant 4)
Some intervention participants described how, during
treatment, they felt their mood improving, that they
were gaining a better understanding of their depression
and learning new skills to better manage their symp-
toms. This was evident in all three studies but particu-
larly apparent in the accounts given by individuals in
trial 2 who had received CBT. Such developments meant
some participants ended treatment feeling positive and
more in control:
I did the course of cognitive behaviour therapy; it altered
the way I think about things. I’ve managed to break the
cycle of the negative thinking, so I’ve sort of gone from a
negative, very depressed person to someone who’s more
positive. It’s just learning the techniques and applying
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them, and it just makes you feel better.… I feel a
different person. (Trial 2, intervention, participant 1)
If you can get yourself into a situation where you’re
exercising regularly, you’ve got the motivation, you’re
getting yourself fit, you have a sense of achievement.…
[T]his perhaps isn’t the right way to say it, but you
cease to be a victim of depression as you are if you’re
having active treatment.… It gives you some sort of a
sense – a sense of self-reliance and self-confidence and
independence. (Trial 1, intervention, participant 14)
Having a clear treatment end point meant therapists
could manage the final session in a way that provided
closure and supported the individual in moving on.
Intervention participants talked about their therapist re-
assuring them that they were now better able to manage
their symptoms and providing them with suggestions of
where they could access further support if necessary
(e.g., from their GP, bereavement counselling, mother
and baby support centre).
When we focused on the usual-care participants’ ac-
counts, there was very little sense of randomisation hav-
ing led to them embarking upon a clear care pathway. A
few participants did talk about seeing their GP every 4
or 6 weeks, and these individuals also reported seeing
the same practitioner and receiving ongoing support,
but this arrangement was described as existing prior to
trial entry. In addition, the other usual-care participants
described rarely seeing their GP and rarely seeing the
same GP. It was also apparent that, owing to the avail-
ability of repeat prescriptions, this could be the situation
even when the individual was on medication and felt he/
she was struggling:
Interviewer: So you tend to just get repeat
prescriptions?
Participant: Yeah, I don’t even speak to anybody.
Interviewer: OK, so when was the last time you
consulted your GP face to face?
Participant: 4–5 months ago…, and that was a different
GP to the one that I saw originally. I haven’t seen the
lady that put me on it [medication] originally for a year.
Interviewer: OK, and how well would you say you’re
coping at the moment?
Participant: Not very well. (Trial 1, usual care,
participant 11)
The variation between usual-care participants regard-
ing what continuity of care they had experienced was
apparent across the three data sets and between partici-
pants involved in the same trial. Thus, it seemed to re-
flect the nature of service delivery in primary care rather
than the nature of usual care within a specific trial, as
well as the fact that some participants had formed a re-
lationship with a specific GP and sought only to consult
that GP, while others had not.
In terms of treatment provided, most individuals who
had consulted their GP had received a 10-minute ap-
pointment and had been prescribed an antidepressant
or, if they were already on medication, a repeat prescrip-
tion. The only other treatment mentioned during the
accounts which had been offered by a GP was a referral
for counselling. Four participants mentioned this treat-
ment, and all four explained that they had needed to
wait months before receiving this care.
When describing being prescribed medication, while
two individuals mentioned that their GP had explained
why medication would be personally beneficial, most
usual-care participants remarked that antidepressants
had been prescribed because they were a quick and easy
way for the GP to deal with their depression:
I haven’t been given very much in the way of different
options by the GP. It was very much being treated by
medication, and really counselling has never been
mentioned, or any other therapies. I mean, I just feel
that when I go into a doctor’s surgery, they have got a
limited amount of time to deal with it.… Medication
was, I suppose, an easy way of dealing with it. (Trial 1,
usual care, participant 18)
In terms of treatment effect, whilst some participants
described medication as stabilising their mood, others
stated they were unsure what effect medication had on
their mental health. In addition, medication was de-
scribed being a ‘crunch’ (trial 1, usual care, participant
11) and as treating the symptoms of depression rather
than the cause. Furthermore, most participants who
were on medication at the time of the interview said
they had been on the same dose for some time. Such
comments gave little sense of individuals feeling that
medication had moved them forward in terms of man-
aging their depression.
View of practitioner
Intervention and usual-care participants who had con-
tinuity in terms of the therapist/GP they consulted de-
scribed them as being good listeners, sympathetic,
supportive and empathising with their situation. Thera-
pists and GPs were also described as being
knowledgeable about depression, although the former
were described as being particularly knowledgeable be-
cause of their training and because they specifically
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worked with patients with depression. Their workload
was viewed as providing them with not only knowledge
but also understanding, which encouraged participants
to talk and placed them in a position of being able to re-
assure individuals:
That really did help, to know that she was seeing other
ladies like, who were similar to me.… I just genuinely
felt I could talk to her because she was somebody that
knew where I was coming from.… She said everybody’s
different and you mustn’t think that “oh, I’m like this
now and that, you know, that I’m never going to get
over this because I have seen people get over it”.
(Trial 3, intervention, participant 19)
The context in which care was provided, as well as
the perceived role of the therapist, also appeared to
encourage intervention participants to discuss their
depression. Most intervention participants’ treatment
sessions lasted about 1 h, giving participants sufficient
time to explain how they were feeling. Intervention
participants talked about these sessions as being for
them, with their therapist tailoring treatment to their
needs and being there to listen and provide advice re-
garding their depression. This gave a sense of partici-
pants viewing these sessions as being about them and
their mental health. For example, one individual said
‘She [the RHV] was really there for me…, specifically
for the post-natal depression’ (Trial 3, intervention,
participant 5). Treatment sessions were also described
as friendly and informal, and there was the suggestion
that individuals felt comfortable confiding in their
therapists because they were not medical
professionals:
You know that it was like a therapy session, but it
was so informal and friendly.… It makes it easier to
discuss things…, whereas if there’s more, you know
stricter … more clinical and formal, you feel like
you don’t wanna sort of give everything, you want
to hold something back. (Trial 2, intervention,
participant 1)
She [the RHV] was the kind of person that was very
friendly, open, she really listened. I felt that like, I felt
sort of like a bond, as if not a stranger or she’s like a
medical person or anything like that. (Trial 3,
intervention, participant 19)
The idea of intervention participants feeling more able
to confide in a non-medical professional was also im-
plied by some participants who commented that they
had felt it important that sessions had not been recorded
in their medical notes:
That was another important thing, that things weren’t
like shared with my GP … those thoughts and stuff like
that, I wouldn’t have like, interviewed so openly.…
That was another thing that I felt confident about …
was that it’s not going to go out to my health visitor or
my GP or the hospital or on my records or something
like that. (Trial 3, intervention, participant 19)
It was evident, though, when we focused on the usual-
care participants’ accounts, that some participants
viewed their GP as someone they could talk openly to.
These participants were those who had continuity in
terms of the GP they saw. They talked about their GP
being someone who would not judge or view them nega-
tively and as someone who could help them with their
depression. Continuity of care appeared to have been
important in terms of establishing this situation:
Interviewer: The next thing is to say, ‘can GPs help
with depression?’
Participant: I think so, yeah, I think so because I feel
like, with my GP, I’ve got a good relationship with him,
and I can go to him and I can, I can talk to him because
[hesitation] he knows, I don’t have to go into everything
that’s happened in my life, and I can go in and just have
a bit of rant at him and feel a bit better. (Trial 2, usual
care, participant 10)
In contrast, other usual-care participants who did not
have continuity of care detailed how they felt their GP
had dismissed their symptoms, had patronised them or
had not listened. Participants had found such interac-
tions very upsetting and had responded by registering
with a different GP or not seeking help, even though
they were aware they needed it:
It was just something about the doctor, I don’t know. She
seemed very patronising.… [S]he made me feel little and
stupid and thick, so I thought “oh, I’m not going back to
see you again.”… I know I need to see her because I
know in myself I’m not feeling right. [This participant
had previously attempted suicide.] But then I don’t
want to go.… [I]t was just her persona towards me, and
I thought, “I can’t, I’m not going to be able to come and
talk to you if I’m really bad”, and I knew that straight
away. (Trial 3, usual care, participant 15)
A few usual-care participants also talked about not
wanting to tell their GP too much because friends and
family used the same practice, which, in their view,
raised issues of confidentiality. It was also evident that
short treatment appointment times were viewed as cur-
tailing discussion:
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You don’t get much time to do that [talk], it’s not like
they’re a person you’re going to have a chat with;
you’re in and you’re out, aren’t you? (Trial 3, usual
care, participant 1)
Discussion
The present study demonstrates that there are important
differences between the experiences of participants ran-
domised to different trial arms regarding engagement
with and access to their allocated care; the amount of
care received; the quality of the practitioner-patient rela-
tionship, especially in terms of continuity; and the
context in which care is delivered. These differences
could affect treatment outcomes between trial arms.
Patients’ treatment expectations can influence the ef-
fect of an intervention [21], and patient preferences have
been shown to affect treatment outcomes in some trials
[22, 23], although authors of a systematic review of trials
that incorporated participants’ preferences concluded
that intervention preferences have limited impact on
their validity [24]. Research has shown that both practi-
tioners and patients may view usual care as substandard
to the intervention [25, 26] and that patients have a
three-fold preference for psychological over pharmaco-
logical interventions [27]. This preference was evident in
the present study. In addition, it has been argued that al-
location to the ‘wrong’ treatment can lead to ‘resentful
demoralisation’ [28], which in turn may result in patients
disengaging from their usual treatment or seeking alter-
native interventions [29]. Whilst there was no evidence
of usual-care patients disengaging from treatment or
seeking additional support, such resentment may create
its own bias by altering the psychological outcomes of
participants so that they ‘under-perform’ on certain out-
come measures [29]. This may be particularly relevant in
depression trials and where self-reported outcome mea-
sures are used.
Individuals randomised to usual care needed to initiate
contact with a practitioner. Patients are often reluctant
to disclose mental health problems to their GP [30, 31],
and in the present study such reluctance meant, for
some usual-care participants, usual care entailed no
change in care or, where treatment had not been initi-
ated pre-trial, no care. In contrast, intervention partici-
pants automatically received opportunities for changes
and increases in care, and the fact that contact was
initiated by the therapist himself/herself probably meant
that this care was accessed shortly after randomisation.
In the present study it was evident that intervention
participants had experienced continuity of care and
viewed this situation as enabling them to build a rela-
tionship with their therapist. Such continuity is particu-
larly valued by patients when psychological issues are
being discussed [32, 33], and patients with depression
who have a constructive relationship with their practi-
tioner are more likely than those who do not to comply
with prescribed medication or physical activity pro-
grammes, to complete therapy and to experience better
treatment outcomes [34–39]. Yet, even if continuity had
not been achieved, it was apparent that intervention
participants received treatment in a context where there
were regular appointments; where participants viewed
their therapist as particularly knowledgeable about de-
pression; and where there was time to talk, which in it-
self can be experienced as therapeutic [13]. It was also a
context in which both the practitioner and patient
expected mental health to be discussed. This expectation
removed the need for patients to initiate a conversation
about their mental health, a process which usual-care
participants described as discouraging them from
consulting a GP. It also removed the possibility that pa-
tients felt unsure whether it would be appropriate to
disclose depressive symptoms, which can be the case in
primary care [30, 40].
There was variation in the extent to which usual-care
participants received continuity of care and the extent to
which patients were regularly seen and regarding follow-
up. In terms of actual treatment provided, though, there
was little variation, with usual care being primarily de-
scribed as consisting of 10-minute appointments and be-
ing prescribed an antidepressant. GPs were described as
having limited ability and interest in treating depression,
and this finding, along with the perception of GPs offer-
ing only medication, is in keeping with the results of
other studies [30, 41].
The GP consultation was rarely described as a context
in which patients felt comfortable discussing their men-
tal health or felt they had time to do so. However, the
usual-care participants who had continuity of care felt
able to talk to their GP and viewed their GP as someone
who could help them. The importance participants
placed on how practitioners interacted with them
supports evidence that suggests patients with depression
value practitioner attributes, such as approachability,
more than the time or treatment the practitioner can
provide [13]. It probably also relates to the fact that, in
the management of depression, the practitioners’ inter-
personal skills will form a core part of the treatment
provided [41].
Having reviewed and synthesised findings from
published qualitative studies describing factors affecting
recruitment into depression trials, Hughes-Morley et al.
[26] found that the reasons individuals took part in de-
pression trials included wanting to access services that
would otherwise not be available to them and believing
the trial would be personally beneficial. The differences
identified in the present study suggest researchers will
struggle to describe or define usual care in a way that
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will reassure potential trial participants that they will re-
ceive a level, quality and consistency of care comparable
to that of individuals randomised to the intervention
arm. In this situation, it may be that researchers need to
accept that clinical equipoise will be difficult to demon-
strate and consider trial designs such as waiting-list
control trials, in which all trial participants eventually
receive the trial intervention, or take into account pa-
tient preferences for a particular treatment [42]. It may
also be that researchers need to consider whether treat-
ment as usual is an acceptable comparator.
Whilst the usual-care arm of a trial may consist of
treatment as usual, as was the case in our study, re-
searchers may choose to define the usual-care arm of
their trial as care that adheres to clinical guidelines or is,
according to current evidence, the best proven therapy
[7, 8]. With research funders requesting patient and
public involvement in the design of clinical research, its
content may also be influenced by patients’ views on
what would be considered acceptable. Researchers may
have concerns about characterising and clearly defining
usual care because doing so could improve its quality
and content, which in turn could reduce the effect size
of the intervention [43]. However, defining usual care ac-
cording to guidelines, evidence and patients’ views
would help ensure usual-care participants received a cer-
tain standard of care and could improve trial recruit-
ment. It might also guard against researchers who want
to demonstrate an intervention effect ignoring,
consciously or not, the standards and experiences of care
associated with usual care.
Researchers in pragmatic trials aim to evaluate inter-
ventions within clinical practice, and therefore the con-
text in which care is provided cannot be separated from
the actual intervention itself. However, researchers may
want to introduce procedures to reduce some of the dif-
ferences identified in the present study to ensure they
are assessing two treatments (i.e., intervention versus
more structured GP care) and to limit the extent to
which contextual factors or modes of delivery affect
treatment outcomes. Possibilities could include request-
ing that GP practices contact patients randomised to
usual care and offer an initial appointment, and provide
continuity of care where possible. Individuals involved in
recruiting trial participants, or informing them of their
treatment allocation, could present usual care as an op-
portunity for the individual to have their treatment
reviewed. They could also proactively address some of
the assumptions and scepticism around care provided in
general practice by highlighting that GPs regularly deal
with depression and that antidepressants are an effective
treatment [44]. They could also mention that, with the
establishment of Improving Access to Psychological
Therapies (IAPT) programme in 2008, GPs now have
greater opportunities to refer patients for psychological
interventions for depression. In addition, as suggested
above, researchers may want to consider whether to try
to standardise usual care. National Institute for Health
and Care Excellence [45] guidance on the management
of depression in adults could be used to inform this
process because it includes clear guidance on which
treatment should be offered and when, as well as how
regularly patients should be followed. Last, researchers
may want to measure variables such as patients’ confi-
dence in their practitioners’ ability to treat depression, as
well as the level of continuity of care experienced, to
better capture participants’ experiences in different trial
arms, and to measure factors that might influence treat-
ment adherence and effectiveness.
Strengths and limitations
The fact that differences between trial arms were identi-
fied across all three data sets increases the confidence
with which conclusions can be drawn. However, the data
synthesised came from interviews with individuals who
were participating in mental health trials that all in-
cluded non-pharmacological interventions. This could
limit the generalisability of the findings because it may
have been that these trials attracted patients who held
particularly negative views towards medication. In
addition, the differences found between the accounts of
intervention and usual-care participants were probably
heightened by the fact that those in the intervention
arms were receiving treatments which actively engaged
the participants, required them to work with a therapist
and aimed to provide them with new skills and insights,
whereas those randomised to usual care received mainly
a treatment which entailed little engagement and that
patients may have viewed as addressing not the cause of
their depression but merely the symptoms [46]. It should
also be noted that the interviews conducted required
participants to recall their treatment and trial experi-
ences. Thus, their accounts were open to post hoc re-
construction and recall bias and may have been shaped
by their overall trial and treatment experiences.
Another limitation is that some of the data were col-
lected 10 years ago. During this period, IAPT services
have increased primary care patients’ access to psycho-
logical treatments [47], so the provision of non-
pharmacological interventions in primary care has chan-
ged. However, as indicated in this paper, antidepressants
remain the first-line treatment for depression in primary
care [48], and prescribing rates for antidepressants con-
tinue to rise [49]. Over the last 10 years, there has been
increasing interest in trial methodology, as evident in
the establishment within this time period of, for ex-
ample, the Medical Research Council Hubs for Trials
Methodology Research and journals such as Trials. The
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design of pragmatic trials therefore may have been re-
fined during this period. Yet, some of the points raised
in this paper (e.g., patients viewing usual care as sub-
standard to the intervention) are still being debated by
those working in clinical trials and not only in the area
of mental health [50]. Additionally, as indicated in the
discussion above, some of our findings resonate with
those of other studies.
Conclusions
Differences exist between the experiences of individuals
who are recruited to mental health trials and allocated
to different treatment arms, in terms accessing treat-
ment, the level of attention and consistency they receive,
and what treatment and practitioner expectations they
have. These differences could affect treatment outcomes
of individuals in different trial arms over and above the
difference between what is assumed to be standard care
and the intervention being tested. Researchers should
consider whether they want to introduce processes to re-
duce some of these differences, whether they want to try
to standardise usual care, and/or whether they want to
adopt specific trial designs that ensure each trial partici-
pant, independent of allocation, feels that he/she benefits
from trial participation. Whilst the focus in the present
study is on mental health trials, many of the points
raised are applicable to trials in other clinical settings.
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